Product Program year 2024 Source: CMS Open Payments

Symdeko

Drug Cystic Fibrosis

NDC 51167-661-01

Open in the dashboard

General payments

$216,660

295 payments

Research payments

$0

0 payments

Through program year 2024, $216,660 in general payments and $0 in research payments were reported against Symdeko (Cystic Fibrosis).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2024 General $5,700 3
2023 General $6,483 4
2022 General $3,419 4
2021 General $6,120 16
2020 General $11,250 20
2019 General $183,689 248

Breakdown

Who paid General payments · program years 2019–2024
  1. Vertex Pharmaceuticals Incorporated $216,660 295 payments
Top recipients General payments · program year 2023
  1. Univ Of Mi Hospitals & Hlth Ctrs Teaching hospital · MI $2,000 31% · 1 payment
  2. Childrens Hospital Corporation Teaching hospital · MA $2,000 31% · 1 payment
  3. Christopher Siracusa Pediatric Pulmonology · Cincinnati, OH $1,283 20% · 1 payment
  4. Dell Seton Medical Center At The Uni Teaching hospital · TX $1,200 19% · 1 payment

Each share is of general payments naming this product in 2023.

Specialties paid General payments · program year 2023
  1. Pediatric Pulmonology Pediatrics $1,283 100% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2023
  1. Massachusetts $2,000 31% · 1 recipient
  2. Michigan $2,000 31% · 1 recipient
  3. Ohio $1,283 20% · 1 recipient
  4. Texas $1,200 19% · 1 recipient

Each share is of general payments naming this product in 2023 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

377

Prescriptions dispensed, refills included

Drug cost

$9,508,301

Paid at the pharmacy, in all

Prescribers

27

With 11 or more claims of it

Medicare Part D drugs matched to SYMDEKO, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Symdeko Tezacaftor/Ivacaftor Same name 27 377 $9,508,301

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 27 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Meredith Wiltsie Nurse Practitioner CA 34 $880,450 None on record
Theresa Heynekamp Pulmonary Disease NM 21 $527,040 None on record
Robert Kempainen Critical Care (Intensivists) MN 18 $463,572 None on record
Abraham Rotbart Internal Medicine FL 15 $375,126 No profile
Samantha Kane Nurse Practitioner PA 14 $454,087 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 27 with Patron
295 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record